We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-2.35%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.85B
AUM Growth
+$132M
Cap. Flow
+$223M
Cap. Flow %
7.84%
Top 10 Hldgs %
64.12%
Holding
111
New
25
Increased
23
Reduced
13
Closed
26

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$172M
2
MET icon
MetLife
MET
+$21.3M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$13.5M
4
AIG icon
American International
AIG
+$13.4M
5
DG icon
Dollar General
DG
+$13M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$32.6M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$28.1M
3
IMGN
Immunogen Inc
IMGN
+$13.7M
4
BABA icon
Alibaba
BABA
+$12.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.93M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 28.65%
2 Healthcare 21.49%
3 Financials 2.87%
4 Communication Services 1.25%
5 Industrials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$731M 25.67%
29,443,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$366M 12.86%
57,517,981
+21,321,962
+59% +$172M
SPY icon
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$288M 10.1%
1,400,000
+200,000
+17% +$40.2M
MRK icon
4
CALL
Merck
MRK
$326B
$102M 3.59%
1,886,400
+1,048,000
+125% +$58.4M
MCD icon
5
CALL
McDonald's
MCD
$194B
$65.6M 2.3%
+700,000
New +$65.5M
AUXL
6
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$58.5M 2.05%
1,700,000
-575,000
-25% -$18.8M
BIIB icon
7
CALL
Biogen
BIIB
$30.4B
$58.4M 2.05%
172,000
+30,000
+21% +$9.71M
JPM icon
8
CALL
JPMorgan Chase
JPM
$950B
$56.3M 1.98%
900,000
+150,000
+20% +$9.03M
YUM icon
9
CALL
Yum! Brands
YUM
$41.4B
$51M 1.79%
973,700
+625,950
+180% +$32.6M
BABA icon
10
Alibaba
BABA
$276B
$49.4M 1.73%
475,000
-125,000
-21% -$12.8M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12B
$43.4M 1.52%
480,000
-70,000
-13% -$5.82M
BAC icon
12
CALL
Bank of America
BAC
$439B
$42.9M 1.51%
2,400,000
+650,000
+37% +$11.1M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.5B
$38.8M 1.36%
400,000
+100,000
+33% +$9.26M
IWM icon
14
CALL
iShares Russell 2000 ETF
IWM
$80.4B
$35.9M 1.26%
300,000
-500,000
-63% -$57.2M
AIG icon
15
CALL
American International
AIG
$42.9B
$33.6M 1.18%
600,000
– –
GWW icon
16
CALL
W.W. Grainger
GWW
$66B
$31.9M 1.12%
125,000
-75,000
-38% -$18.5M
INCY icon
17
Incyte
INCY
$26B
$30M 1.05%
410,000
-30,000
-7% -$1.96M
GM icon
18
CALL
General Motors
GM
$81.7B
$29.7M 1.04%
850,000
– –
TEVA icon
19
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$28.8M 1.01%
500,000
-100,000
-17% -$5.57M
PCYC
20
DELISTED
PHARMACYCLICS INC
PCYC
$27.5M 0.97%
225,000
– –
WFC icon
21
CALL
Wells Fargo
WFC
$263B
$27.4M 0.96%
+500,000
New +$26.5M
BMRN icon
22
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$27.1M 0.95%
300,000
+100,000
+50% +$8.32M
MET icon
23
CALL
MetLife
MET
$62.7B
$27M 0.95%
561,000
-448,800
-44% -$21.3M
NKTR icon
24
Nektar Therapeutics
NKTR
$2.39B
$25.6M 0.9%
110,000
– –
GE icon
25
CALL
GE Aerospace
GE
$377B
$25.3M 0.89%
208,662
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2014 Portfolio in Review

As of Q4 2014, Artal Group held 111 positions worth $2.85B, up 4.9% from $2.72B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Artal Group deployed $223M of net new capital in Q4 2014, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was MetLife: 448,800 shares worth $21.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Alibaba, an estimated $12.8M trimmed.

  • Artal Group's largest Q4 2014 buy was MetLife: 448,800 shares worth $21.6M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q4 2014, an estimated $172M increase.
  • Artal Group's biggest Q4 2014 reduction was Alibaba, cutting an estimated $12.8M.
  • Artal Group fully exited AUXILIUM PHARAMCEUTICALS INC in Q4 2014, selling an estimated $32.6M.
  • Artal Group's ten largest holdings make up 64% of its $2.85B portfolio in Q4 2014.
  • Artal Group opened 25 new positions and closed 26 in Q4 2014.
  • Artal Group's portfolio value rose 4.9% quarter-over-quarter to $2.85B.

Based on Artal Group's 13F filing for Q4 2014, filed 13 Feb 2015.